Breast Neoplasm

cancer family

Identifier: CI-CAN-00000007
Entity page: /cancer/breast-neoplasm ↗
Edges: 14,761

Neighbours: 15 genes38 drugs10 trials
Drawn: 60 of 63 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,147 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Breast Neoplasm approved for …APPROVED_FOR30 of 44show all (up to 200)
← approved for	Trastuzumabmonoclonal_antibody 11 source records aggregated	supports	mesh_therapeutic_area	Breast Neoplasm	11	Regulatory	ema	graph →
← approved for

Paths

Strongest chains

Gene → variant → drug chains anchored in this cancer (or a descendant), ranked by source-native evidence level then support, with the approval and trial registry hops when they exist.

ERBB2 Amplification TrastuzumabFDA US 1998-09-25110 active / 586 trials
Curatedlevel Asensitivity· support 15civicObservedERBB2 altered in 4.7% (182 / 3,879 cases, largest of 6 cohorts)Regulatoryapproved for Malignant Breast Neoplasm (4 approval records)context: Malignant Breast Neoplasm, HER2-Positive Breast Carcinoma
PIK3CA H1047R FulvestrantFDA US 2002-04-25101 active / 294 trials
Curatedlevel Asensitivity· support 3civicObservedPIK3CA altered in 36% (1,401 / 3,879 cases, largest of 20 cohorts)Regulatoryapproved for Malignant Breast Neoplasm (12 approval records)context: Malignant Breast Neoplasm, HER2-Positive Breast Carcinoma
PIK3CA C420R FulvestrantFDA US 2002-04-25101 active / 294 trials
Curatedlevel Asensitivity· support 2civicObservedPIK3CA altered in 36% (1,401 / 3,879 cases, largest of 20 cohorts)Regulatoryapproved for Malignant Breast Neoplasm (12 approval records)context: Malignant Breast Neoplasm
PIK3CA E542K FulvestrantFDA US 2002-04-25101 active / 294 trials
Curatedlevel Asensitivity· support 2civicObservedPIK3CA altered in 36% (1,401 / 3,879 cases, largest of 20 cohorts)Regulatoryapproved for Malignant Breast Neoplasm (12 approval records)context: Malignant Breast Neoplasm
PIK3CA E545A FulvestrantFDA US 2002-04-25101 active / 294 trials
Curatedlevel Asensitivity· support 2civicObservedPIK3CA altered in 36% (1,401 / 3,879 cases, largest of 20 cohorts)Regulatoryapproved for Malignant Breast Neoplasm (12 approval records)context: Malignant Breast Neoplasm
PIK3CA E545D FulvestrantFDA US 2002-04-25101 active / 294 trials
Curatedlevel Asensitivity· support 2civicObservedPIK3CA altered in 36% (1,401 / 3,879 cases, largest of 20 cohorts)Regulatoryapproved for Malignant Breast Neoplasm (12 approval records)context: Malignant Breast Neoplasm
PIK3CA E545G FulvestrantFDA US 2002-04-25101 active / 294 trials
Curatedlevel Asensitivity· support 2civicObservedPIK3CA altered in 36% (1,401 / 3,879 cases, largest of 20 cohorts)Regulatoryapproved for Malignant Breast Neoplasm (12 approval records)context: Malignant Breast Neoplasm
PIK3CA E545K FulvestrantFDA US 2002-04-25101 active / 294 trials
Curatedlevel Asensitivity· support 2civicObservedPIK3CA altered in 36% (1,401 / 3,879 cases, largest of 20 cohorts)Regulatoryapproved for Malignant Breast Neoplasm (12 approval records)context: Malignant Breast Neoplasm

Each hop keeps its own claim category: cohort alteration frequency (observed, cases ≥ 20), CIViC predictive edge (curated, level as stated by CIViC), regulatory approval (authority, jurisdiction, date as published), trial count (registry). A missing hop is shown as missing — never filled in. Not treatment guidance.

Breast Neoplasm investigated for …INVESTIGATED_FOR15 of 255show all (up to 200)
← investigated for	Tucatinibsmall_molecule	unknown	4	Breast Neoplasm	1	Curated	chembl	graph →
← investigated for	Trastuzumab Emtansineadc	unknown	4	Breast Neoplasm	1	Curated	chembl	graph →
← investigated for	Trastuzumab Deruxtecanadc	unknown	4	Breast Neoplasm	1	Curated	chembl	graph →
← investigated for	Trastuzumab Deruxtecanadc	unknown	4	Breast Neoplasm	1	Curated	chembl	graph →
← investigated for	Trastuzumabmonoclonal_antibody	unknown	4	Breast Neoplasm	1	Curated	chembl	graph →
← investigated for	Toremifenesmall_molecule	unknown	4	Breast Neoplasm	1	Curated	chembl	graph →
← investigated for	Tamoxifensmall_molecule	unknown	4	Breast Neoplasm	1	Curated	chembl	graph →
← investigated for	Talazoparibsmall_molecule	unknown	4	Breast Neoplasm	1	Curated	chembl	graph →
← investigated for	Sacituzumab Govitecanadc	unknown	4	Breast Neoplasm	1	Curated	chembl	graph →
← investigated for	Ribociclibsmall_molecule	unknown	4	Breast Neoplasm	1	Curated	chembl	graph →
← investigated for	Pertuzumabmonoclonal_antibody	unknown	4	Breast Neoplasm	1	Curated	chembl	graph →
← investigated for	Palbociclibsmall_molecule	unknown	4	Breast Neoplasm	1	Curated	chembl	graph →
← investigated for	Paclitaxelsmall_molecule	unknown	4	Breast Neoplasm	1	Curated	chembl	graph →
← investigated for	Olaparibsmall_molecule	unknown	4	Breast Neoplasm	1	Curated	chembl	graph →
← investigated for	Neratinibsmall_molecule	unknown	4	Breast Neoplasm	1	Curated	chembl	graph →

Breast Neoplasm altered in cohorts of …ALTERED_INderived15 of 276show all (up to 200)
← altered in cohorts of	OBSCN 806 / 1,098 cases (73 %) · ssm · TCGA-BRCA · largest of 3 cohorts	—	—	Breast Invasive Carcinoma, NOS	3	Observed	gdc	graph →
← altered in cohorts of	PIK3C2B 804 / 1,098 cases (73 %) · ssm · TCGA-BRCA	—	—	Breast Invasive Carcinoma, NOS	1	Observed	gdc	graph →
← altered in cohorts of	LRRN2 803 / 1,098 cases (73 %) · ssm · TCGA-BRCA	—	—	Breast Invasive Carcinoma, NOS	1	Observed	gdc	graph →
← altered in cohorts of	MDM4 803 / 1,098 cases (73 %) · ssm · TCGA-BRCA	—	—	Breast Invasive Carcinoma, NOS	1	Observed	gdc	graph →
← altered in cohorts of	NFASC 803 / 1,098 cases (73 %) · ssm · TCGA-BRCA	—	—	Breast Invasive Carcinoma, NOS	1	Observed	gdc	graph →
← altered in cohorts of	NID1 803 / 1,098 cases (73 %) · ssm · TCGA-BRCA	—	—	Breast Invasive Carcinoma, NOS	1	Observed	gdc	graph →
← altered in cohorts of	PLEKHA6 802 / 1,098 cases (73 %) · ssm · TCGA-BRCA	—	—	Breast Invasive Carcinoma, NOS	1	Observed	gdc	graph →
← altered in cohorts of	PPP1R15B 801 / 1,098 cases (73 %) · ssm · TCGA-BRCA	—	—	Breast Invasive Carcinoma, NOS	1	Observed	gdc	graph →
← altered in cohorts of	ASPM 800 / 1,098 cases (73 %) · ssm · TCGA-BRCA · largest of 2 cohorts	—	—	Breast Invasive Carcinoma, NOS	2	Observed	gdc	graph →
← altered in cohorts of	CDK18 800 / 1,098 cases (73 %) · ssm · TCGA-BRCA	—	—	Breast Invasive Carcinoma, NOS	1	Observed	gdc	graph →
← altered in cohorts of	CHI3L1 799 / 1,098 cases (73 %) · ssm · TCGA-BRCA	—	—	Breast Invasive Carcinoma, NOS	1	Observed	gdc	graph →
← altered in cohorts of	CNTN2 799 / 1,098 cases (73 %) · ssm · TCGA-BRCA	—	—	Breast Invasive Carcinoma, NOS	1	Observed	gdc	graph →
← altered in cohorts of	DSTYK 799 / 1,098 cases (73 %) · ssm · TCGA-BRCA	—	—	Breast Invasive Carcinoma, NOS	1	Observed	gdc	graph →
← altered in cohorts of	EXOC8 799 / 1,098 cases (73 %) · ssm · TCGA-BRCA	—	—	Breast Invasive Carcinoma, NOS	1	Observed	gdc	graph →
← altered in cohorts of	LYST 799 / 1,098 cases (73 %) · ssm · TCGA-BRCA	—	—	Breast Invasive Carcinoma, NOS	1	Observed	gdc	graph →

Breast Neoplasm investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 319show all (up to 200)
→ investigated in trials for	Trastuzumabmonoclonal_antibody 586 trials (110 active) · roll-up of the cancer and its descendants	—	—	Breast Neoplasm	586	Observed	clinicaltrials	graph →
→ investigated in trials for	Paclitaxelsmall_molecule 575 trials (127 active) · roll-up of the cancer and its descendants	—	—	Breast Neoplasm	575	Observed	clinicaltrials	graph →
→ investigated in trials for	Cyclophosphamidesmall molecule 499 trials (88 active) · roll-up of the cancer and its descendants	—	—	Breast Neoplasm	499	Observed	clinicaltrials	graph →
→ investigated in trials for	Docetaxelsmall_molecule 399 trials (59 active) · roll-up of the cancer and its descendants	—	—	Breast Neoplasm	399	Observed	clinicaltrials	graph →
→ investigated in trials for	Capecitabinesmall_molecule 351 trials (86 active) · roll-up of the cancer and its descendants	—	—	Breast Neoplasm	351	Observed	clinicaltrials	graph →
→ investigated in trials for	Letrozolesmall molecule 299 trials (72 active) · roll-up of the cancer and its descendants	—	—	Breast Neoplasm	299	Observed	clinicaltrials	graph →
→ investigated in trials for	Fulvestrantsmall_molecule 294 trials (101 active) · roll-up of the cancer and its descendants	—	—	Breast Neoplasm	294	Observed	clinicaltrials	graph →
→ investigated in trials for	Carboplatinsmall molecule 287 trials (93 active) · roll-up of the cancer and its descendants	—	—	Breast Neoplasm	287	Observed	clinicaltrials	graph →
→ investigated in trials for	Doxorubicinsmall_molecule 278 trials (41 active) · roll-up of the cancer and its descendants	—	—	Breast Neoplasm	278	Observed	clinicaltrials	graph →
→ investigated in trials for	Tamoxifensmall_molecule 240 trials (41 active) · roll-up of the cancer and its descendants	—	—	Breast Neoplasm	240	Observed	clinicaltrials	graph →
→ investigated in trials for	Pembrolizumabmonoclonal antibody 230 trials (116 active) · roll-up of the cancer and its descendants	—	—	Breast Neoplasm	230	Observed	clinicaltrials	graph →
→ investigated in trials for	Pertuzumabmonoclonal_antibody 183 trials (82 active) · roll-up of the cancer and its descendants	—	—	Breast Neoplasm	183	Observed	clinicaltrials	graph →
→ investigated in trials for	Anastrozolesmall molecule 181 trials (43 active) · roll-up of the cancer and its descendants	—	—	Breast Neoplasm	181	Observed	clinicaltrials	graph →
→ investigated in trials for	Exemestanesmall molecule 177 trials (34 active) · roll-up of the cancer and its descendants	—	—	Breast Neoplasm	177	Observed	clinicaltrials	graph →
→ investigated in trials for	Bevacizumabmonoclonal_antibody 176 trials (21 active) · roll-up of the cancer and its descendants	—	—	Breast Neoplasm	176	Observed	clinicaltrials	graph →

Breast Neoplasm studied in …STUDIED_INderived10 of 13,867show all (up to 200)
→ studied in	NCT01113970Phase 1/Phase 2 · completed Study of a Novel Indibulin Dosing Schedule for the Treatment of Metastatic Breast Cancer · condition mapped CURATED_BROADER · 13,867 trials mapped (3,690 active)	—	—	Malignant Breast Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT01758445Phase 2 · active not recruiting Proton Radiation for Stage II/III Breast Cancer · condition mapped ONTOLOGY_EXACT · 13,867 trials mapped (3,690 active)	—	—	Breast Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT01766297Phase 2 · recruiting Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer · condition mapped ONTOLOGY_EXACT · 13,867 trials mapped (3,690 active)	—	—	Breast Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT02465060Phase 2 · active not recruiting Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) · condition mapped ONTOLOGY_EXACT · 13,867 trials mapped (3,690 active)	—	—	Breast Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02883062Phase 2 · active not recruiting Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer · condition mapped PROBABILISTIC · 13,867 trials mapped (3,690 active)	—	—	Breast Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT03598257Phase 2 · active not recruiting Radiation Therapy With or Without Olaparib in Treating Patients With Inflammatory Breast Cancer · condition mapped ONTOLOGY_EXACT · 13,867 trials mapped (3,690 active)	—	—	Breast Inflammatory Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04072952Phase 1/Phase 2 · completed A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Participants With ER+/HER2- Locally Advanced or Metastatic Breast Cancer · condition mapped CURATED_EXACT · 13,867 trials mapped (3,690 active)	—	—	Malignant Breast Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT04720209NA · active not recruiting Taking AIM at Breast Cancer · condition mapped CURATED_EXACT · 13,867 trials mapped (3,690 active)	—	—	Malignant Breast Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT04906395Phase 3 · active not recruiting Ovarian Suppression Evaluating Subcutaneous Leuprolide Acetate in Breast Cancer · condition mapped CURATED_EXACT · 13,867 trials mapped (3,690 active)	—	—	Malignant Breast Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT05038735Phase 3 · active not recruiting Study to Assess the Efficacy and Safety of Alpelisib Plus Fulvestrant in Participants With HR-positive (HR+), HER2-negative, Advanced Breast Cancer After Treatment With a CDK4/6 Inhibitor and an Aromatase Inhibitor. · condition mapped CURATED_EXACT · 13,867 trials mapped (3,690 active)	—	—	Malignant Breast Neoplasm	1	Observed	clinicaltrials	graph →